leadf
logo-loader
NASDAQ:GNPX

Genprex, Inc.

Receive alerts
Market:
NASDAQ
Market Cap:
$127.85 m
Price
2.69 USD
Change
-2.89%
52 weeks high
7.72
52 weeks low
2.25

In brief

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. 

Snapshot

The US FDA has granted Fast Track Designation for REQORSA for non-small cell lung cancer in combination with AstraZeneca's Tagrisso for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso alone